Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
AssigneeNeurimmune Holding AG
InventorsJan Grimm, Aubin Michalon
Life of this patent
Estimating the term…
Abstract
Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
Claims13
A recombinant anti-transthyretin (TTR) antibody that binds mutated, misfolded, misassembled, and/or aggregated TTR species and/or fragments thereof and does not recognize physiological TTR species, wherein the antibody comprises a human fragment crystallizable (Fc) region of an IgG1 isotype and comprises complementarity determining regions (CDRs), wherein:
- (i) CDR-H1 comprises the amino acid sequence of SEQ ID NO:
- 104;
- (ii) CDR-H2 comprises the amino acid sequence of SEQ ID NO:
- 105;
- (iii) CDR-H3 comprises the amino acid sequence of SEQ ID NO:
- 106;
- (iv) CDR-L1 comprises the amino acid sequence of SEQ ID NO:
- 107;
- (v) CDR-L2 comprises the amino acid sequence of SEQ ID NO:
- 108;
- and
- (vi) CDR-L3 comprises the amino acid sequence of SEQ ID NO:
- 109.
Dependencies are inferred from the claim text.